Flixotid Evochaler (micronized) aerosolum 125 mcg. 120 doses


Manufacturer: France

Adults and teenagers aged 16 and over Prophylactic use in severe asthma in patients requiring high doses of inhaled or oral corticosteroids. Patients who are treated with high doses of oral corticosteroids to reduce or eliminate the use of oral corticosteroids. Children and teenagers from 4 to 16 yEars and Nose old Treatment of asthma exacerbations. Appropriate maintenance therapy may be supplemented with the use of a metered-dose aerosol or powder inhaler. Inhaled fluticasone propionate has a powerful glucocorticoid anti-inflammatory effect in the lungs. It reduces the symptoms and exacerbation of asthma in patients who were previously treated only with bronchodilators or in combination with other preventive medications. Short symptomatic episodes of exacerbation may generally be relieved when using fast-acting bronchodilators, but longer-term exacerbations require additional corticosteroid therapy as early as possible to control inflammation.



active substance: fluticasone propionate

1 dose contains fluticasone propionate 50 mcg or 125 mcg

excipients: propellant HFA 134a.

Metered dose inhalation aerosol.

white or almost white suspension.

Anti-asthma drugs for inhalation use. Glucocorticoids. ATX code R03B A05.

Flixotid Evochaler Pharmacological properties.


Fluticasone propionate, when administered by inhalation in recommended doses, has a pronounced glucocorticoid anti-inflammatory effect in the lungs. This is manifested in a decrease in both symptoms and exacerbations of asthma with a decrease in the number and intensity of adverse reactions compared with the systemic use of corticosteroids.

Flixotid Evochaler Pharmacokinetics.

The average systemic bioavailability of Flixotide Evohaler according to studies in healthy volunteers was 28.6%. Systemic absorption is carried out mainly through the respiratory system, first quickly, then – for a long time. The remainder of the inhalation dose may be swallowed.

Product safety data
Toxicological studies have shown the presence of effects typical of strong GCS, but in doses many times higher than those indicated for therapeutic use. In studies on the effect of the drug on reproductive function and the presence of teratogenic properties of the drug, no new data were found. Fluticasone propionate has no mutagenic activity in vitro and in vivo. In experiments on animals, it was shown that there is no carcinogenic potential in the preparation, as well as irritating and sensitizing properties.

Preventive treatment of bronchial asthma


Mild asthma: patients who need periodic symptomatic treatment with bronchodilators daily.

Moderate asthma: Patients with unstable asthma or worsening with existing prophylactic therapy or therapy with bronchodilators alone.

Severe asthma: Patients with severe chronic asthma and patients dependent on systemic corticosteroids for adequate symptom control. Once inhaled fluticasone propionate is started, many of these patients will be able to significantly reduce or completely eliminate oral corticosteroid use.

Prophylactic anti-asthma treatment, including in the case when control of asthma symptoms has not been achieved against the background of treatment with other anti-asthma drugs.

Hypersensitivity to the components of the drug.